Feasibility of the Adoptive Transfusion of Allogenic Human Leukocyte Antigen-Matched Natural Killer Cells in Patients With Renal Cell Carcinoma

Journal of Immunotherapy

Volumn 23, Issue 4, 2000, Pages 499-504

  Frohn, Christoph ^a   Durek, Christoph ^a   Böhle, Andreas ^a   Schlenke, Peter ^a   Jocham, Dieter ^a   Kirchner, Holger ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Adoptive immunotherapy; Feasibility trial; Natural killer cells; Renal cell carcinoma

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEASIBILITY STUDY; FEVER; HUMAN; KIDNEY CARCINOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; ADULT; AGED; ANTIGENS, CD; CARCINOMA, RENAL CELL; FEASIBILITY STUDIES; HLA-C ANTIGENS; HUMANS; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 0033936726     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200007000-00014     Document Type: Article

References (31)

1. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485-92.
2. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993; 71:2358-70.
3. Negrier S, Michon J, Floret D, et al. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 1991; 9:1363-70.
4. Sparano JA, Fisher RI, Weiss GR, et al. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother 1994; 16:216-23.
5. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-97.
6. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76:824-32.
7. Schwarz RE, Vujanovic NL, Hiserodt JC. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res 1989; 49:1441-6.
8. Whiteside TL, Ernstoff MS, Nair S, Kirkwood JM, Herberman RB. In vitro Generation and in vivo effects of adherent lymphokine activated killer cells and IL-2 in patients with solid tumors. In: Schmidt RE, ed. Natural Killer Cells: Biology and Application. Basel: Karger Verlag, 1990, 293-302.
9. Vujanovic NL, Yasumura S, Hirabayashi H, et al. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol 1995; 154:281-9.
10. Hercend T, Farace F, Baume D, et al. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma. J Biol Response Mod 1990; 9:546-55.
11. Escudier B, Farace F, Angevin E, et al. Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur J Cancer 1994; 30A:1078-83.
12. Gumperz JE, Parham P. The enigma of the natural killer cell. Nature 1995; 378:245-8.
13. Atzpodien J, Kirchner H, Hänninen E, et al. Interleukin-2 in combination with interferon-alpha and 5-flourouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A:66.
14. Council of Europe Press. Guide to the Preparation, Use and Quality Assurance of Blood Components. Strasbourg, France: Council of Europe Press, 1995.
15. Mandelboim O, Reyburn HT, Sheu EG, Vales Gomez M, Davis DM, Pazmany L, et al. The binding site of NK receptors on HLA-C molecules. Immunity 1997; 6:341-50.
16. Frohn C, Schlenke P, Ebel B, et al. DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. J Immunol Methods 1998; 218:155-60.
17. Fisher M, Chapman JR, Ting A, Morris PJ. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions. Vox Sang 1985; 49:331-5.
18. Erlich P. Über den jetztigen Stand der Karzinomforschung. Ned Tijdsch voor Geenesk 1909; 1:273-290.
19. Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144:53-8.
20. Lotzova E, Savary CA. Dichotomy in reactivity of IL-2-Activated human lymphocyte subsets against normal and malignant hematopoietic cells. In: Schmidt RE, ed. Natural Killer Cells: Biology and Clinical Application. Basel: Karger Verlag, 1990, 280-4.
21. Van den Eynde B, Peeters O, De Backer O, et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995; 182:689-98.
22. Garrido F, Cabrera T, Concha A, et al. Natural history of HLA expression during tumour development. Immunol Today 1993; 14:491-9.
23. Whiteside TL, Ernstoff MS, Nair S, Kirkwood JM, Herberman RB. In vitro Generation and in vivo effects of adherent lymphokine activated killer cells and IL-2 in patients with solid tumors. In: Schmidt RE, ed. Natural Killer Cells: Biology and Application. Basel: Karger Verlag, 1990, 293-302.
24. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319:675-8.
25. Balch CM, Tilden AB, Dougherty PA, Cloud GA. Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg 1983; 198:192-9.
26. Lai P, Rabinowich H, Crowley Nowick PA, et al. Alterations in expression and function of signal transducing proteins in tumor-associated T and natural killer cells in ovarian carcinoma. Biochem Soc Trans 1997; 25:218S.
27. Rabinowich H, Suminami Y, Reichert TE, et al. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996; 68:276-84.
28. Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27:321-7.
29. Trentin L, Cerutti A, Zambello R, et al. Interleukin-15 promotes the growth of leukemic cells of patients with B- cell chronic lymphoproliferative disorders. Blood 1996; 87:3327-35.
30. Arima N, Matsushita K, Suruga Y, et al. IL-2-induced growth of CD8+ T cell prolymphocytic leukemia cells mediated by NF-kappaB induction and IL-2 receptor alpha expression. Leuk Res 1998; 22:265-73.
31. Boasberg PD, Tokita KM, Terasaki PI, Wang X. Lymphocyte transfusion therapy for cancer patients. Blood 1996; 87:3522-3.